Pharsight

Plx Pharma patents expiration

1. Vazalore patents expiration

VAZALORE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101637 PLX PHARMA Methods of treating inflammation with compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Mar, 2022

(1 year, 6 months ago)

US8865187 PLX PHARMA Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity
Mar, 2022

(1 year, 6 months ago)

US10786444 PLX PHARMA PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(9 years from now)

US10646431 PLX PHARMA PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(9 years from now)

US9226892 PLX PHARMA pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(9 years from now)

US9216150 PLX PHARMA pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
Sep, 2032

(9 years from now)

Drugs and Companies using ASPIRIN ingredient

Market Authorisation Date: 14 January, 2013

Treatment: Treatment/prevention of cardiovascular disease; Temporary reduction of fever; Temporary relief of minor aches and pains; A method of targeting release of a non-steroidal anti-inflammatory drug (nsaid)...

Dosage: CAPSULE;ORAL

More Information on Dosage

VAZALORE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic